Aldevron is hosting a webinar on September 8, 2026, titled How Early is Too Early to Start Thinking About Manufacturing? For gene-modified cell therapies, choices made during plasmid design can create advantages or challenges that persist all the way through commercialization.

Aldevron is proud to be part of Danaher.  Danaher’s science and technology leadership puts Aldevron’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.  Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.